Table 1.
Breakdown of Included Individuals With Available Viral Antibody Assays, San Francisco Bay Area Adult Glioma Study
| Glioma Cases | Grade II/III Glioma | Grade IV Glioma | Non-glioma Controls | |
|---|---|---|---|---|
| Individuals with any IgG data | ||||
| No. | 1378 | 483 | 761 | 1124 |
| Mean age (SE) | 50.8 (2.1) | 44.3 (2.0) | 56.7 (1.7) | 55.6 (2.0) |
| % Male | 58.6 | 55.9 | 62.5 | 50.2 |
| % White | 86.9 | 84.5 | 88.6 | 87.8 |
| % IDH mutated | 30.2 | 71.2 | 8.2 | |
| Median months survival (IQR) | 25.3 (128.6) | 130.0 (251.6) | 16.0 (14.4) | |
| % on Dexamethasone | 34.2 | 20.9 | 45.6 | |
| No. with specific IgG (% seropositive) | ||||
| VZV | 1374 (94.3%) | 480 (95.4%) | 760 (93.8%) | 1121 (94.4%) |
| EBV | 781 (92.6%) | 293 (91.8%) | 415 (93.5%) | 907 (94.6%) |
| HSV | 775 (72.8%) | 290 (69.0%) | 412 (76.7%) | 910 (74.0%) |
| CMV | 781 (54.8%) | 293 (53.2%) | 415 (55.7%) | 911 (54.7%) |
IQR = Interquartile range